Fortress Biotech, Inc. cash flow to debt ratio of -88.53% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Fortress Biotech, Inc.'s free cash flow has increased -30.90% from $-95.19M last year to $-65.78M, signaling increasing performance

Fortress Biotech, Inc.'s debt to equity ratio is 0.33, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Fortress Biotech, Inc.'s debt has decreased relative to shareholder equity from 3.34 last year to 0.33 today, signaling strengthened financials

Fortress Biotech, Inc. has negative EBITDA, making leverage ratio unreliable

Fortress Biotech, Inc.'s interest coverage ratio is -5.83, which means that the company struggles to meet interest obligations, signaling financial risk.

Fortress Biotech, Inc.'s profit margin has increased (-342.15%) in the last year from -79.75% to 193.12%, signaling increasing performance

Fortress Biotech, Inc.'s short-term assets of $123.84M exceed its short-term liabilities of $49.74M

Fortress Biotech, Inc.'s return on assets of 35.80% is higher than the 5.00% threshold, indicating efficient asset utilization

Fortress Biotech, Inc.'s return on equity of 163.88%, is higher than 15.00%, indicating good performance

Fortress Biotech, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Fortress Biotech, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Fortress Biotech, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Fortress Biotech, Inc. has negative free cash flow, indicating cash burn

Fortress Biotech, Inc.'s yearly earnings has increased -114.82% since last year from $-46.00M to $6.82M, signaling increasing performance

Fortress Biotech, Inc.'s yearly revenue has increased 6.18% since last year from $57.67M to $61.24M, signaling increasing performance

ROIC -20.91% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Fortress Biotech, Inc.'s 3-year revenue CAGR of -5.83% is negative, indicating declining revenue over the past 3 years

Fortress Biotech, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Fortress Biotech, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Fortress Biotech, Inc. has insufficient data to evaluate this check.

Fortress Biotech, Inc. has an earnings yield of 108.61%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Fortress Biotech, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Fortress Biotech, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Fortress Biotech, Inc. is overvalued relative to its fair value price of -7.55 based on Earnings Fair Value model

Fortress Biotech, Inc. has a PEG-ratio under 1 which is considered undervalued

Fortress Biotech, Inc. has a price-to-book ratio of 0.58x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Fortress Biotech, Inc. has a price-to-sales ratio of 1.78x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue